Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally. [1][2][3][4][5]

Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity —...

1 day ago · With amycretin, Novo Nordisk expects to improve on the efficacy of its blockbuster drug semaglutide, sold under the brand names Ozempic and Wegovy. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that have rapidly gained in popularity in recent years due to their significant weight loss effects.

6 days ago · Novo Nordisk reported today that amycretin, an investigational glucagon-like peptide-1 (GLP-1) and amylin receptor agonist, led to significant weight reductions in individuals with overweight or obesity in a phase 1b/2a clinical trial. 1 The randomized, placebo-controlled 5-part trial enrolled 125 adults and assessed the safety, tolerability, pharmacokinetics, and proof-of …

5 days ago · A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.

4 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.

6 days ago · The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Mar 15, 2024 · Amycretin stands as a groundbreaking development in the realm of weight loss medications, primarily due to its dual-action mechanism. It is designed to mimic the effects of two crucial hormones:

Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin.

Mar 7, 2024 · At an investor event on Thursday, Novo Nordisk shared data from an early stage clinical trial of an experimental weight loss drug called amycretin, an oral treatment that trial …